SciSparc (SPRC) Liabilities from Discontinued Operations (2016 - 2017)

SciSparc (SPRC) posted Liabilities from Discontinued Operations of 697000.0 for Q3 2017, up 7.56% sequentially from 648000.0 in Q2 2017.

SciSparc (SPRC) Liabilities from Discontinued Operations (2016 - 2017) Analysis & Trends

SciSparc has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 697000.0 in Q3 2017.

Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 697000.0 in Q3 2017, while the trailing twelve-month figure through Sep 2017 was 697000.0 (changed N/A YoY) and the FY2016 annual result came in at 672000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations climbed to 697000.0 in Q3 2017 per SPRC's latest filing, from 648000.0 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 1114000.0 in Q1 2017 and troughed at 648000.0 in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	SciSparc	831,418.60	831,418.60	-

Download Data